Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.

Florence Duffaud,Jean-Yves Blay,Olivier Mir,Pascaline Boudou-Rouquette,Sophie Piperno-Neumann,Nicolas Penel,Emmanuelle Bompas,Corinne Delcambre,Elsa Kalbacher,Antoine Italiano,Olivier Collard,Christine Chevreau,Antoine Thyss,Nicolas Isambert,Jessy Delaye,Nicolas De Sousa Carvalho,Camille Schiffler,Corinne Bouvier,V. Vidal,Sylvie Chabaud

Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.

2018

11504Background: Oral multikinase inhibitor REG has shown activity in GIST and non-adipocytic soft tissue sarcomas. We designed REGOBONE as a non-comparative phase II, double-blind, PL-controlled t...

Keywords:

Placebo
Phases of clinical research
Regorafenib
Oncology
Metastatic osteosarcoma
Pathology
Sarcoma
Medicine
Internal medicine
in patient
GiST
Soft tissue

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations